NASDAQ:MDWD - MediWound Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $7.50
Forecasted Upside: 56.25 %
Number of Analysts: 4
Breakdown:
0 Sell Ratings
0 Hold Ratings
4 Buy Ratings
0 Strong Buy Ratings

^$4.80 As of 06/18/2021 01:00 AM ET

▲ +0.2 (4.35%)

1 month | 3 months | 12 months

Get New MediWound Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for MDWD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDWD

^$7.50

▲ +56.25% Upside Potential

This price target is based on 4 analysts offering 12 month price targets for MediWound in the last 3 months. The average price target is $7.50, with a high forecast of $10.00 and a low forecast of $6.00. The average price target represents a 56.25% upside from the last price of $4.80.

Buy

The current consensus among 4 contributing investment analysts is to buy stock in MediWound. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/27/2019

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/26/2020

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/24/2020

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/22/2020

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/21/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/21/2021

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/20/2021

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/19/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
6/10/2021	Oppenheimer	Reiterated Rating	Buy	$7.00	High
3/2/2021	Aegis	Initiated Coverage	Buy	$10.00	High
2/26/2021	HC Wainwright	Boost Price Target	Buy	$5.50 ➝ $7.00	High
9/23/2020	BTIG Research	Initiated Coverage	Buy	$6.00	Medium
8/7/2020	HC Wainwright	Reiterated Rating	Buy		Medium
7/1/2020	HC Wainwright	Reiterated Rating	Buy	$5.50	High
6/30/2020	Oppenheimer	Reiterated Rating	Buy	$7.00	Low
5/21/2020	HC Wainwright	Reiterated Rating	Buy	$5.50	Low
5/18/2020	Oppenheimer	Initiated Coverage	Buy	$7.00	High
1/7/2020	HC Wainwright	Reiterated Rating	Buy	$5.50	Low
11/15/2019	HC Wainwright	Reiterated Rating	Buy	$5.50	Medium
8/14/2019	Oppenheimer	Lower Price Target	Outperform	$15.00 ➝ $7.00	High
8/5/2019	HC Wainwright	Initiated Coverage	Buy	$5.50	High
3/25/2019	Oppenheimer	Set Price Target	Buy	$15.00	Low
1/22/2019	Oppenheimer	Set Price Target	Buy	$15.00	Medium
11/14/2018	Oppenheimer	Set Price Target	Buy	$14.00	High
9/25/2018	Wells Fargo & Company	Set Price Target	Buy	$11.00	Medium
9/24/2018	Oppenheimer	Set Price Target	Buy	$14.00	Medium
9/5/2018	Oppenheimer	Set Price Target	Buy	$14.00	Low
8/8/2018	Wells Fargo & Company	Set Price Target	Buy	$11.00	Medium
8/7/2018	Oppenheimer	Set Price Target	Buy	$14.00	Medium
6/11/2018	Oppenheimer	Set Price Target	Buy	$14.00	High
5/29/2018	Wells Fargo & Company	Reiterated Rating	Buy		Medium
5/10/2018	Oppenheimer	Set Price Target	Buy	$14.00	Medium
3/20/2018	Wells Fargo & Company	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $8.00	High
3/19/2018	Oppenheimer	Boost Price Target	Outperform ➝ Outperform	$10.00 ➝ $12.00	High
12/8/2017	Oppenheimer	Set Price Target	Buy	$10.00	High
11/16/2017	SunTrust Banks	Set Price Target	Buy	$9.00	N/A
11/16/2017	Oppenheimer	Set Price Target	Buy	$10.00	N/A
10/17/2017	Oppenheimer	Set Price Target	Buy	$10.00	N/A
9/28/2017	Cowen	Initiated Coverage	Outperform	$9.00	Medium
9/28/2017	Jefferies Financial Group	Reiterated Rating	Buy	$10.00	Medium
9/18/2017	Oppenheimer	Reiterated Rating	Buy	$10.00	Low
8/25/2017	Jefferies Financial Group	Set Price Target	Buy	$10.00	High
6/26/2017	SunTrust Banks	Reiterated Rating	Buy		Low
5/25/2017	Aegis	Reiterated Rating	Buy	$11.00	Low
5/8/2017	Oppenheimer	Set Price Target	Buy	$10.00	Low
3/22/2017	Oppenheimer	Reiterated Rating	Buy		High
3/8/2017	Oppenheimer	Reiterated Rating	Outperform	$10.00	Low
2/9/2017	Oppenheimer	Set Price Target	Buy	$10.00	N/A
2/1/2017	Oppenheimer	Reiterated Rating	Outperform	$10.00	N/A
11/28/2016	Aegis	Initiated Coverage	Buy	$11.00	N/A
8/17/2016	Wells Fargo & Company	Initiated Coverage	Outperform	$14.00	N/A
7/29/2016	Jefferies Financial Group	Lower Price Target	Buy	$15.00 ➝ $13.00	N/A

(Data available from 6/20/2016 forward)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Today's Range

Now: $4.80

$4.57

$4.80

50 Day Range

MA: $4.22

$3.38

$5.26

52 Week Range

Now: $4.80

$2.37

$6.07

Volume

207,780 shs

Average Volume

149,606 shs

Market Capitalization

$130.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52

Frequently Asked Questions

What sell-side analysts currently cover shares of MediWound?

The following sell-side analysts have issued research reports on MediWound in the last twelve months: Aegis, BTIG Research, HC Wainwright, Oppenheimer Holdings Inc., TheStreet, and Zacks Investment Research.
View the latest analyst ratings for MDWD.

What is the current price target for MediWound?

4 Wall Street analysts have set twelve-month price targets for MediWound in the last year. Their average twelve-month price target is $7.50, suggesting a possible upside of 56.3%. Aegis has the highest price target set, predicting MDWD will reach $10.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $6.00 for MediWound in the next year.
View the latest price targets for MDWD.

What is the current consensus analyst rating for MediWound?

MediWound currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MDWD will outperform the market and that investors should add to their positions of MediWound.
View the latest ratings for MDWD.

What other companies compete with MediWound?

Other companies that are similar to MediWound include Canopy Rivers, Natural Alternatives International, Mannatech, FitLife Brands, Nutra Pharma, Glucose Health, Happiness Biotech Group, Heyu Biological Technology, Tauriga Sciences, Cyanotech, GLG Life Tech, Exactus, Entia Biosciences, Rock Creek Pharmaceuticals and Beleave.

How do I contact MediWound's investor relations team?

MediWound's physical mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company's listed phone number is 972-8932-4010 and its investor relations email address is [email protected] The official website for MediWound is www.mediwound.com.